5. Peterson M: *Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs*. New York, Farrar Straus and Giroux, 2008
6. Abramson J: *Overdo\$Ed. America: The Broken Promise of American Medicine*. New York, HarperCollins, 2004
7. Moynihan R, Cassels A: *Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All Into Patients*. New York, Nation Books, 2006
8. Senator Chuck Grassley of Iowa: Available at grassley.senate.gov/news/Article.cfm?customel_dataPageID_1502=18067; grassley.senate.gov/news/Article.cfm?customel_dataPageID_1502=21624
9. United States Senate Special Committee on Aging: Kohl Hearing Considers Effects of Billions in Drug, Device Funding on Medical Education in America. July 29, 2009. Available at aging.senate.gov/hearing_detail.cfm?id=316395&
10. American Medical Student Association: AMSA PharmFree Scorecard 2009. www.amsascorecard.org/executive-summary
11. Campbell EG, Weissman JS, Ehringhaus S, et al: Institutional academic industry relationships. *JAMA* 2007; 298:1779–1786
12. Academic CME in North America: The 2008 AAMC/SACME Harrison Survey. Available at services.aamc.org/publications/showfile.cfm?file=version131.pdf&prd_id=260&prv_id=319&pdf_id=131
13. Perlis RH, Perlis CS, Wu Y, et al: Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. *Am J Psychiatry* 2005; 162:1957–1960
14. Buchkowsky SS, Jewesson PJ: Industry sponsorship and authorship of clinical trials over 20 years. *Ann Pharmacother* 2004; 4:579–585
15. Heres S, Davis J, Maino K, et al: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. *Am J Psychiatry* 2006; 163:185–194
16. Safer DJ: Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. *J Nerv Ment Dis* 2002; 190:583–592
17. Melander H, Ahlqvist-Rastad J, Meijer G, et al: Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. *BMJ* 2003; 326:1171–1173
18. Jibson MD: Medical education and the pharmaceutical industry: managing an uneasy alliance. *Acad Psychiatry* 2006; 30:36–39
19. Feinstein RE, Rothberg B, Weiner N, et al: University of Colorado Department of Psychiatry Evidence-Based Medicine Educational Project. *Acad Psychiatry* 2008; 32:525–530
20. Freedman R, Lewis DA, Michels R, et al: Conflict of interest—an issue for every psychiatrist. *Am J Psychiatry* 2009; 166:274
21. Kraemer HC, Kupfer DJ: Size of treatment effects and their importance to clinical research and practice. *Biol Psychiatry* 2006; 59:990–996

Real Doctors

“Mum and Dad won’t think you are a real doctor if you don’t get bloody,” replied my sister when I first confided that I was thinking of psychiatry. Years later, I tell my students the measure of “real doctors” is not how they deal with their patients’ blood but how they deal with their tears.

Jason P. Caplan
St. Joseph’s Hospital and Medical Center,
Phoenix, Arizona